Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study: Erratum

医学 Golimumab公司 强直性脊柱炎 内科学 脊柱炎 疾病 儿科 梅德林 外科 物理疗法
出处
期刊:Jcr-journal of Clinical Rheumatology [Lippincott Williams & Wilkins]
卷期号:32 (6): e228-e228
标识
DOI:10.1097/rhu.0000000000002365
摘要

In August 2022 issue of Journal of Clinical Rheumatology, the article “Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study” requires correction. The sponsor recently became aware of data errors related to the Bath Ankylosing Spondylitis Metrology Index (BASMI) and the UCSF Enthesitis Index that occurred during the study. The ensuing tabular and in-text corrections are provided hereinafter. The corrected BASMI results are in Table 1 and in the Supplemental Digital Content 1 that are provided below. TABLE 1 - Correction. Baseline Demographics and Clinical Characteristicsa Early Disease Late Disease Placebo n=25 IV Golimumab n=35 Placebo n=28 IV Golimumab n=24 BASMI (0–10)bc 4.3 (1.4) 4.3 (1.8) 4.9 (1.3) 5.4 (1.5) Enthesitis score, UCSF (0–17)bc 5.2 (4.4) 4.7 (3.0) 6.3 (4.4) 6.6 (4.4) aMean (SD) reported unless otherwise stated.bEarly disease: placebo, n=24.cLate disease: IV golimumab, n=21. Supplemental Digital Content 1 - Correction. Mean (SD) Changes From Baseline in Additional Efficacy Outcomes Week 16 Week 52 Early Disease Late Disease Early Disease Late Disease Outcome (score range) Placebo (N=25) IV Golimumab (N=35) Placebo (N=28) IV Golimumab (N=24) Placebo→IV Golimumab (N=25) IV Golimumab (N=35) Placebo→IV Golimumab (N=28) IV Golimumab (N=24) Bath Ankylosing Spondylitis Metrology Index (0-10)b −0.3 (0.9) −0.6 (0.9) 0 (0.6) −0.6 (0.8) −0.9 (1.1) −0.7 (0.7) −0.6 (0.9) −0.5 (1.0) Enthesitis score (0-17)b −0.3 (3.2) −2.9 (2.9) −0.8 (2.8) −2.2 (3.1) −2.2 (4.2) −3.3 (2.4) −2.8 (3.0) −3.2 (5.6) bFor Week 16, early disease N=24 placebo, late disease N=28 placebo and N=21 IV golimumab; for Week 52, early disease N=24 placebo→IV golimumab, late disease N=21 IV golimumab. The corrected Enthesitis results are in the 3rd paragraph of Demographics and Baseline Disease Characteristics subsection and 3rd paragraph of Clinical Efficacy by Disease Duration Status within the Results section, Table 1, and Supplemental Digital Content 1 provided below. 3rd paragraph of Demographics and Baseline Disease Characteristics changes: When comparing baseline enthesitis in late disease, vs early disease mean enthesitis scores were updated from 5.9–6.5 vs. 4.6–4.9 to 6.3–6.6 vs. 4.7–5.2, respectively. 3rd paragraph of Clinical Efficacy by Disease Duration Status changes: The mean (SD) improvement in enthesitis from baseline to week 16 in the placebo group with early disease was updated from 0.1 [3.6] to -0.3 [3.2]. These changes are minor and do not impact our interpretation of the data or conclusions regarding the efficacy of golimumab in ankylosing spondylitis. The authors apologize for these errors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无奈的大聪明完成签到,获得积分10
1秒前
yize发布了新的文献求助20
1秒前
moooonu完成签到,获得积分10
1秒前
1秒前
eleanor发布了新的文献求助30
1秒前
1秒前
1秒前
Maestro_S的应助被li采纳,获得10
2秒前
deityxq完成签到,获得积分10
2秒前
2秒前
木头人发布了新的文献求助10
3秒前
充电宝的应助被替代采纳,获得10
3秒前
ddong完成签到,获得积分10
3秒前
山人出窍发布了新的文献求助10
3秒前
风笛完成签到,获得积分20
3秒前
daytoy发布了新的文献求助10
3秒前
haozaizai完成签到,获得积分10
4秒前
李健的应助被Lufy采纳,获得10
4秒前
4秒前
cc完成签到 ,获得积分10
4秒前
clx完成签到,获得积分10
5秒前
Eiffer完成签到,获得积分10
5秒前
5秒前
单薄树叶完成签到,获得积分0
5秒前
Sisi发布了新的文献求助10
5秒前
5秒前
6秒前
天天快乐的应助被Tardigrade采纳,获得10
6秒前
6秒前
7秒前
故意的若风完成签到,获得积分10
7秒前
Misaky32完成签到,获得积分20
7秒前
QianShenYu完成签到,获得积分10
7秒前
轻松夏槐完成签到,获得积分10
7秒前
8秒前
英俊的铭的应助被一氧化二氢采纳,获得10
8秒前
8秒前
小超超超腻害完成签到,获得积分10
9秒前
江江的应助被每天都很好采纳,获得10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174559
求助须知:如何正确求助?哪些是违规求助? 9566586
关于积分的说明 21787112
捐赠科研通 7768831
什么是DOI,文献DOI怎么找? 3431746
关于科研通互助平台的介绍 2555956
邀请新用户注册赠送积分活动 2477100